Novel nicotine degrading enzyme variants
AssigneesAntidote Therapeutics, Inc., Board of Regents, The University of Texas System
InventorsMatthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
Life of this patent
Estimating the term…
Abstract
Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
Claims21
1-80. (canceled)
A method of treating nicotine addiction, facilitating smoking cessation, treating nicotine poisoning or treating nicotine toxicity comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a nicotine-degrading enzyme variant, wherein the variant comprises an amino acid sequence having at least 90% sequence identity to a sequence selected from (i) SEQ ID NO:
- 1 and (ii) SEQ ID NO:
- 1 having an N-terminal deletion of up to 52 amino acids, and wherein the variant comprises at least one substitution at an amino acid position selected from positions 91, 104, 106, 107, 217, 250, 340, 355, 366, 381, 427, 462, and 463 of SEQ ID NO:1, and has nicotine-degrading activity, provided that if the variant is F335V then the variant has an N-terminal deletion of up to 52 amino acids.
Dependencies are inferred from the claim text.